ReviewBritish journal of pharmacology2020
Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension.
Review in British journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Insulin Resistance Indices and Subclinical Left Ventricular Systolic Dysfunction in Adults: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2026Pooled it
- Transcriptomic Features of Thyroid Signaling Disorders in Experimental Pulmonary Arterial Hypertension.Bulletin of experimental biology and medicine · 2026Article
- Review
- Pulmonary Arterial Hypertension Induces Compensatory Increase of Left Ventricular Contractility Indexes in Rats in Response to Its Filling Insufficiency.Bulletin of experimental biology and medicine · 2025Article
- Pulmonary vascular remodeling in Fra-2 transgenic mice is driven by type 2 inflammation and accompanied by pulmonary vascular hyperresponsiveness.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- The beneficial and detrimental effects of prolactin hormone on metabolic syndrome: A double-edge sword.Journal of cellular and molecular medicine · 2024Review
- A Systematic Review of Metabolic Syndrome: Key Correlated Pathologies and Non-Invasive Diagnostic Approaches.Journal of clinical medicine · 2024Review
- The advent of RNA-based therapeutics for metabolic syndrome and associated conditions: a comprehensive review of the literature.Molecular biology reports · 2024Review
- Metabolic pathways, genomic alterations, and post-translational modifications in pulmonary hypertension and cancer as therapeutic targets and biomarkers.Frontiers in pharmacology · 2024Article
- Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension.Pulmonary circulation · 2023Review
- The Role of Oxidative Stress and Antioxidants in Cardiovascular Comorbidities in COPD.Antioxidants (Basel, Switzerland) · 2023Review
- New Drugs and Therapies in Pulmonary Arterial Hypertension.International journal of molecular sciences · 2023Review
- Identification of diagnostic biomarkers for idiopathic pulmonary hypertension with metabolic syndrome by bioinformatics and machine learning.Scientific reports · 2023Article
- The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure.Frontiers in cardiovascular medicine · 2023Review
- Myeloid-derived suppressor cells and pulmonary hypertension.Frontiers in immunology · 2023Review
- The alterations in molecular markers and signaling pathways in chronic thromboembolic pulmonary hypertension, a study with transcriptome sequencing and bioinformatic analysis.Frontiers in cardiovascular medicine · 2022Article
- Proteomic and Metabolomic Analyses of Right Ventricular Failure due to Pulmonary Arterial Hypertension.Frontiers in molecular biosciences · 2022Article
- Neurohormonal modulation in pulmonary arterial hypertension.The European respiratory journal · 2021Review
- High-fat diet attenuates the improvement of hypoxia-induced pulmonary hypertension in mice during reoxygenation.BMC cardiovascular disorders · 2021Article
- Safety of surgical denervation of the common hepatic artery in insulin-resistant dogs.Physiological reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Pulmonary vascular disease, including pulmonary arterial hypertension (PAH), is increasingly recognized to be affected by systemic alterations including up-regulation of the renin-angiotensin-aldosterone system and perturbations to metabolic pathways, particularly glucose and fat metabolism. There is increasing preclinical and clinical data that each of these pathways can promote pulmonary vascular disease and right heart failure and are not simply disease markers. More recently, trials of therapeutics aimed at neurohormonal activation or metabolic dysfunction are beginning to shed light on how interventions in these pathways may affect patients with PAH. This review will focus on underlying mechanistic data that supports neurohormonal activation and metabolic dysfunction in the pathogenesis of PAH and right heart failure as well as discussing early translational data in patients with PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.